B+
Bull case
25%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
HRMY
Harmony BiosciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Record WAKIX growth, reiterated $1.0-$1.04 billion 2026 revenue guidance, increasing patient counts, and a progressing BP-205 pipeline support continued positive operating momentum [#SEC-8K-2026-08-04].
Posture
Constructive
Lead driver
Sentiment
What changed
6 setup hits (3d) with net bullish as of 2026-09-09.
What can break
BP-205 remains an early-stage clinical program; future efficacy, safety, enrollment, or timing outcomes are uncertain.
Momentum
75
Value
71
Sentiment
75
Setup hits (3d)
6 · Net Bullish
AI TargetsBase $47.36 · Bull $52.00 · Bear $35.00Analysis 2026-09-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $47.36
Why
Momentum75 · Δ7d -11.2
Value71 · Δ7d -0.0
Sentiment75 · Δ7d +4.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 6 setup hits (3d) with net bullish as of 2026-09-09.
- • Sentiment remains the lead driver in the composite, 7D delta +4.4.
Contradictions & invalidation
- • BP-205 remains an early-stage clinical program; future efficacy, safety, enrollment, or timing outcomes are uncertain.
- • Cost of products sold increased to 24.2% of product revenue in Q2, partly due to royalties tied to the Novitium license agreement.
- • The positive Q2 print and guidance reaffirmation appear partly reflected in the shares, while future upside depends on execution, successful pipeline development, and regulatory outcomes.
Catalyst clock
2026-12-31
BP-205 clinical development milestones
Lead driver: Sentiment · See AI snapshot
Momentum
75
9% active weight
Current posture
7d trendSoftening
Δ7d
-11.2
Δ21d
-4.2
Value
71
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
75
62% active weight
Current posture
7d trendImproving
Δ7d
+4.4
Δ21d
+4.9
Why this grade
Composite grade A. Momentum 75.3 / Value 70.9 / Sentiment 74.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-09. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$47.36
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$35.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.22B
Beta
0.84
Shares Out
58.24M
P/E (TTM)
11.6
P/S (TTM)
2.56
P/FCF (TTM)
7.13
Rev YoY
+30.3%
EPS YoY
+88.6%
Gross Margin
+72.9%
Op Margin
+24.0%
Net Debt
-$540.27M
Current Ratio
3.48
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data